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Abstract
Background: [18F]-tetrafluoroborate is a PET radiotracer taken up by the sodium/iodide symporter (NIS). Albeit the
in vivo behavior in rodents is similar to the 99mTc-pertechnetate, no studies exist in primates or in humans. The
aims of this study were to evaluate the biodistribution of [18F]-tetrafluoroborate in non-human primates with PET
and to estimate the absorbed dose in organs.
Methods: Whole-body PET imaging was done in a Siemens ECAT HR+ scanner in two male Macaca fascicularis
monkeys. After an i.v. injection of 24.93 ± 0.05 MBq/kg of [18F]-tetrafluoroborate, prepared by isotopic exchange of
sodium tetrafluoroborate with [18F]-fluoride under acidic conditions, eight sequential images from the head to the
thigh (five beds) were collected for a total duration of 132 min. The whole-body emission scan was reconstructed
applying attenuation and scatter corrections. After image reconstruction, three-dimensional volumes of interest
(VOIs) were hand-drawn on the PET transaxial or coronal slices of the frame where the organ was most
conspicuous. Time-activity curves for each VOI were obtained, and the organ residence times were calculated by
integration of the time-activity curves. Human absorbed doses were estimated using the OLINDA/EXM software and
the standard human model.
Results: [18F]-tetrafluoroborate was able to discriminate clearly the thyroid gland with an excellent signal-to-noise
ratio. Most of the radiotracers (residence time) are localised in the organs that express NIS (stomach wall, salivary
glands, thyroid, olfactory mucosa), are involved in excretion (kidneys and bladder), or reflect the vascular phase
(heart and lungs). Considering the OLINDA source organs, the critical organs were the stomach wall, thyroid and
bladder wall, with absorbed doses lower than 0.078 mGy/MBq. The effective dose was 0.025 mSv/MBq.
Conclusions: [18F]-tetrafluoroborate is a very useful radiotracer for PET thyroid imaging in primates, with a
characteristic biodistribution in organs expressing NIS. It delivers an effective dose slightly higher than the
dose produced by 99mTc-pertechnetate but much lower than that produced by radioiodine in the form of
131INa, 123INa, or 124INa.
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Background
The sodium/iodide symporter (NIS) is a plasma mem-
brane glycoprotein that mediates the active transport of
iodide in the thyroid and other NIS-expressing cells. NIS
also mediates active iodide transport in other tissues,
including salivary glands, gastric mucosa and lactating
mammary glands. Due to its expression in only a small
number of tissues, NIS provides the basis for the effect-
ive diagnostic and therapeutic management of thyroid
cancer and its metastases with radioiodine [1–3]. More
recently, tumor-selective expression of exogenous NIS
has been proposed as a new strategy to deliver high
absorbed doses selectively to tumors using radioiodine
therapy for non-thyroidal cancers [4, 5]. Additionally,
NIS has also been used as an imaging reporter gene [6].
Traditionally, imaging of NIS for diagnosis of disease
and monitoring treatment for thyroid cancer and hyper-
thyroidism has been performed using the gamma emit-
ters [131I]iodine and [123I]iodine. However, imaging of
these radionuclides has limitations due to the reduced
resolution and sensitivity of SPECT. Moreover, the rela-
tive long half-life of these radionuclides produces
undesirable high absorbed doses. SPECT images with
99mTc-pertechnetate are of high resolution, but PET
technique offers better resolution and sensitivity than
SPECT images and, moreover, allows a quantitative ana-
lysis. More recently, [124I]iodine, a positron emitter, has
been applied in dose planning in radionuclide therapy
[7, 8]. However, PET imaging of NIS with 124I has also
some drawbacks. Iodine-124 has a complex decay
scheme with a low abundance of positrons (23 %). It also
emits high energy γ photons, some of which are very
close to the 511 keV energy window or compete in
abundance with the positron decay (Emax = 1.69 MeV,
10 %). These may interfere with annihilation photons
leading to increased background noise and poor image
quality. Moreover, the availability of iodine-124 is se-
verely limited due to its complex production. Finally, its
long half-life (4.18 days) results in an unjustifiably high
absorbed dose to the patient.
In contrast, the ideal PET tracer for NIS would be
based on 18F because of its good imaging characteris-
tics: short half-life (110 min), high positron yield
(97 %), low positron energy (Emax = 0.634 MeV) and
ready availability by production on a medical cyclo-
tron. In this context, the [18F]-tetrafluoroborate PET
radiotracer has been synthesised by isotopic exchange
with tetrafluoroborate ion (BF4
−) under acidic condi-
tions [9]. BF4
− is a substrate for NIS, as has been
demonstrated by electrochemical studies and accumu-
lation in the thyroid of rats [10, 11]. The usefulness
of this new radiotracer to visualise thyroid and other
organs expressing NIS has previously been described
in preclinical PET/CT images in rodents [9].
Due to the broad applications of NIS in diagnostic
and therapeutic strategies, a PET radiotracer for its
imaging would be of great utility [12]. To promote
the clinical application of this novel radioligand in
humans, we studied the biodistribution and calculated
the absorbed radiation exposure after intravenous ad-
ministration of [18F]-tetrafluoroborate in cynomolgus
monkeys (Macaca fascicularis). Primates were used in
this preclinical investigation as their metabolism and
physiology are closer to those of humans than those




The synthesis of [18F]-tetrafluoroborate was carried out
using an automated labeling protocol developed as
described earlier [9, 13]. Briefly, [18F]-fluoride trapped in a
QMA cartridge was eluted with 1.5 mol/L HCl into a
reactor that contained sodium tetrafluoroborate; the reac-
tion mixture was heated to 120 °C for 10 min, cooled to
25 °C, passed through a silver ion-loaded cation exchange
cartridge and two Sep-Pak Light Alumina N and sterile
filtered. The product was sterile and pyrogen-free.
Subjects/experimental animals
All animal experiments were performed in accordance
with the European Council Directive 86/609/EEC and ac-
cording to a protocol approved by the Ethical Committee
for Animal Testing of the University of Navarra (ref: 026/
11). Two male healthy cynomolgus monkeys (M. fascicu-
laris, 4.47 and 7.06 kg) were used in this study. The ani-
mals fasted overnight with free access to water up to 2 h
before the PET scan. Anaesthesia was initially induced by
intramuscular injections of ketamine (10 mg/kg) and mid-
azolam (1 mg/kg) to allow preparation and handling of
the animals and maintained with a mixture of ketamine
(5 mg/kg) and midazolam (0.5 mg/kg). Once in the PET
facility, the animals were placed on the scanner bed in a
prone position and safely attached to keep the position
during the whole scan. The animals were covered with
blankets to maintain body temperature. Two intravenous
lines on both saphenous veins were inserted, one for the
administration of the radiotracer and the other to obtain
blood samples during the study. The heart rate, respir-
ation and body temperature were monitored and kept in
the normal range throughout the imaging sessions.
Data acquisition
Imaging of each animal consisted of eight whole-body
PET studies acquired successively using an ECAT
EXACT HR+ scanner (Siemens/CTI, Knoxville, TN) in a
static 2D mode. A scan from a single bed position com-
prises 63 slices with a 2.46-mm slice thickness, for
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covering an axial field of view of 15.5 cm [14]. The total
axial field of view scanned for emission and transmission
scans was 69 cm, encompassing the whole body of the
animals. This was accomplished by acquiring five bed
positions with an overlap of seven slices. Prior to tracer
injection, a whole-body transmission scan was obtained
using 68Ge rod sources for 5 min at each bed position.
The attenuation correction factors were obtained after
segmentation of the measured reconstructed attenuation
map. Image acquisition started immediately after intra-
venous administration of 24.93 ± 0.05 MBq/kg [18F]-tet-
rafluoroborate. Each whole-body frame increased the
duration over time for each position to compensate for
18F half-life. The time between successive bed positions
was 12 s and between whole-body frames was about
30 s. The scanning sequence is presented in Table 1 and
Fig. 1. The total duration of the emission scanning was
132 min, and the total duration of the transmission and
emission scanning was approximately 160 min.
Venous blood samples were collected at 0, 0.25, 4, 10,
21, 35, 50, 70, 115 and 130 min after [18F]-tetrafluorobo-
rate administration. The blood samples were weighed
and radioactivity measured in a NaI(Tl) well counter,
calibrated with a 68Ge sample cross-calibrated with the
germanium source used for the standard PET scanner
calibration.
PET reconstruction
The 2D whole-body emission scans were reconstructed
using the ordered-subset expectation maximisation algo-
rithm (two iterations and eight subsets) applying attenu-
ation and scatter corrections (ECAT 7.2.2 software,
Siemens/CTI). A Gaussian post reconstruction filter
with a 4-mm FWHM kernel was applied. A brain mode
and a zoom factor of 2 were also applied in the recon-
struction. The five bed positions of each WB acquisition
(128 × 128 × 63 matrix) were assembled in a volume with
128 × 128 × 269 voxels, with a 2.6 × 2.6 × 2.6 mm3 voxel
size.
Image analysis
Image analysis was performed using PMOD 3.0 software
(PMOD Technologies Ltd, Zurich, Switzerland;
www.pmod.com). The eight whole-body ECAT images
were assembled to obtain a dynamic study file. Three-
dimensional volumes of interest (VOIs) were contoured
on the PET transaxial or coronal slices. After a careful
visual inspection of the images, VOIs were drawn on the
emission frame where the organs were most clearly seen,
depending on organ uptake kinetics. Lung VOIs were
drawn on the transmission image. The identifiable
source organs analysed were as follows: lungs, brain,
heart, kidneys, stomach, urinary bladder, thyroid, olfac-
tory mucosa, esophagus, salivary glands (parotid, sublin-
gual, submandibular) and whole body. The VOIs were
projected onto each whole-body PET image and visually
verified. Then, the total activity of each organ VOI and
frame was determined.
In order to have a proper calibration of the scanner
for monkey’s acquisition, the organ activity values were
corrected for recovery relative to a large VOI that in-
cluded the entire body for each frame, as previously de-
scribed [15]. Thus, the activity value for each source
organ at every time point was scaled to the measured re-
covery for the individual frames (decay corrected).
The activity in each organ VOI was decayed to the bed
midtime reversing the 18F decay correction done by the
ECAT reconstruction software to each bed within each
frame. The organs extending through two bed positions
in the assembled whole-body image were decayed to the
midtime between the corresponding beds.
Time-activity curves (TAC) expressing the percentage
of the injected dose (% ID) at the measured time (bed
midtime) were obtained by dividing the VOI activity by
the administered activity of [18F]-tetrafluoroborate.
Residence time and absorbed dose calculations
For each organ, the TAC of the percentage of injected
activity was plotted versus time. Data were fitted by
trapezoidal approximations followed by exponential
decay with the physical half-life from the last measured
radioactivity concentration, assuming that the decline in
radioactivity after this time point occurred by physical
decay only, without any further biologic clearance, thus
obtaining more conservative values than those obtained
adjusting mathematical functions to the experimental
values. The area under the curve is equivalent to the
residence time.
The human absorbed dose in each organ and effective
dose were estimated using the residence times and the
model for a 70-kg adult in the OLINDA/EXM 1.1 soft-
ware program (Vanderbilt University) [16]. It was as-
sumed that the biodistribution in the monkey was the
same as it would be in humans. Then, no scaling of the
Table 1 Acquisition sequences for PET studies
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macaque biodistribution data was used to estimate hu-
man absorbed doses. No loss of urine or faecal matter
was observed in these animals during the PET study.
Thus, corrections to the absorbed dose calculations for
radioactivity loss through these routes were not needed.
The residence times for the spleen and red marrow were
calculated from the blood residence time. For the spleen,
the residence time was calculated from the blood fraction
of the spleen, which is 1.5 % of its volume [17]. For the
red marrow, its residence time is taken from [18, 19]:
Arm ¼ 0:19= 1–0:39ð ÞABlood ð1Þ
The blood residence time was estimated using the
TAC of the drawn samples, assuming that 5.4 % of the
monkey’s mass was blood and subtracting the fractions
assigned to the spleen and red marrow.
No bladder voiding was assumed in the dosimetry cal-
culation, as the monkeys were not catheterised during
the whole-body PET studies. We estimated the biologic
half-life in the bladder by a fit to a single exponential
increase-to-maximum fit to the decay corrected bladder
TAC. It was considered that the [18F]-tetrafluoroborate
clearance through the urinary pathway was complete un-
less the activity accumulated in the stomach at the end
of the PET study. These parameters were used to esti-
mate the residence time for [18F]-tetrafluoroborate in
the bladder using the dynamic bladder model in the
OLINDA/EXM software program, with the assumption
of a 2.4-h voiding interval.
Absorbed dose estimates for organs not available within
the phantom employed in OLINDA/EXM (parotid and
submandibular glands) were performed using the unit-
density sphere model incorporated in the software. Thus,
the OLINDA/EXM-generated dose coefficients for 18F for
a time-integrated activity coefficient (residence time) of
1 MBq-h/MBq were fitted against the sphere masses using
a power-law model of the form:
d ¼ a mb ð2Þ
where d is the dose coefficient, a and b are fitting pa-
rameters and m is the sphere mass [20]. Using these fit-
ting parameters, we calculated the mean organ absorbed
dose per unit administered activity for each part of the
paired organ by multiplying the output of Eq. (2) by the
corresponding residence time. The density and radio-
nuclide distribution were assumed to be uniform in this
method of calculation. For each part of the parotid and
submandibular salivary glands, the individual mass used
were 18 and 9.9 g, considering the mean volumes re-
ported by Jentzen et al. [21] and a 1 g/cm3 density.
The residence times for all of the source organs were
summed and subtracted from the theoretic total resi-
dence time value of T1/2/ln(2) to calculate the residence
time of the remainder in the body, where T1/2 is the
radioactive half-life of 18F (1.83 h).
Results
Radiochemistry
[18F]-tetrafluoroborate was prepared in greater than
95 % radiochemical purity as shown by radio–thin-layer
chromatography and radio–high-performance liquid
chromatography.
Biodistribution and [18F]-tetrafluoroborate kinetics
Dynamic PET revealed the pattern and kinetics of
[18F]-tetrafluoroborate distribution and clearance dur-
ing the 132 min after a bolus intravenous administra-
tion. The whole-body images of [18F]-tetrafluoroborate
Fig. 1 Scanning sequence for dynamic whole-body acquisition. Outline of the scanning sequences. Time required for repositioning and starting
each frame was approximately 30 s
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biodistribution at different time intervals are shown in
Fig. 2 and in a 3D video (Additional file 1). [18F]-tetra-
fluoroborate was able to discriminate clearly the thy-
roid gland with an excellent signal-to-noise ratio even
at the first minutes of the study (frame 2, 3, 5 min). In
addition, uptake was observed in the organs that also
express NIS, like the stomach wall, salivary glands
(mainly parotids) and olfactory mucosa. Some radio-
activity was detected in the esophagus from minute 40
and hypothesised to originate from the swallowing of
saliva. The stomach wall was the organ with the highest
uptake; however, this uptake was not homogeneous,
distinguishing two different areas. A slight activity was
observed in the choroid plexus, but not in the testes.
Finally, since [18F]-tetrafluoroborate is excreted via the
urinary route, cumulative activity was observed in the
urinary bladder.
Individual source organ TACs for the percentage of
the [18F]-tetrafluoroborate-injected activity are shown in
Fig. 3, reflecting the visual analysis. Initial peaks of
radioactivity in the heart and lungs are related to the
vascular phase, and relative important accumulation
trend was observed in the urinary bladder and stomach.
Other organs expressing NIS also had accumulation,
but in smaller amounts. In the case of thyroid, the
uptake remained stable during the study. On the
other hand, the total blood radioactivity concentration
peaked within the first minute after the injection of
[18F]-tetrafluoroborate and gradually decreased thereafter
(Fig. 4). Both animals showed a similar biodistribution
pattern.
Absorbed dose estimate
Residence time of the selected organs in male cynomol-
gus macaques are shown in Table 2. The stomach, red
marrow, urinary bladder and lungs had long residence
times. The organs within the VOIs were clearly visible
compared to the background but accounted for less than
one quarter of the maximum theoretical residence time
(2.635 h). Most of the injected tracer (~75 %) localised
outside the VOIs modeled in the phantoms used by
OLINDA/EXM, suggesting a low concentration of tracer
distributed in the large compartments and organs and
considered as “remainder” by OLINDA/EXM.
Results of the OLINDA/EXM 1.1 dose calculations for
the PET studies of [18F]-tetrafluoroborate are given in
Table 3. The data are presented as mean ± SD. The relative
contribution of the source organs to the absorbed dose for
a given tissue is determined by their respective S values.
The stomach wall received the highest absorbed dose
(0.079 mGy/MBq), making it the limiting organ. The other
key organs with high absorbed dose were the urinary blad-
der wall (0.048 mGy/MBq), thyroid (0.042 mGy/MBq)
and kidneys (0.022 mGy/MBq). The effective dose was
0.0247 mSv/MBq.
A high variability (variation coefficient greater than
15 %) in measured residence time was found in the urin-
ary bladder contents, brain, stomach, heart and lungs,
while high variability in estimated absorbed doses was
found only in the urinary bladder wall and stomach wall.
This was most likely due to the physical and functional
clearance rates within these organs involved with the ex-
cretion process.
Discussion
The aims of this work were to perform PET imaging of a
non-human primate and to estimate the human absorbed
dose before clinical use of [18F]-tetrafluoroborate in
human PET studies. Monkeys are genetically closer to
humans, so they are supposed to be the closest model of
human metabolism. Some PET dosimetry studies with
other radiotracers have compared the biodistribution and
absorbed radiation dosimetry data obtained from humans
and rodents or non-human primates [15, 17, 22, 23]. Des-
pite biodistribution patterns being quite similar between
species with all radiotracers, human effective dose using
monkey data seems to be overestimated, with exposures
to individual organs both over- and underestimated de-
pending on the radiotracer. For example, Doss et al. [23]
state that for the hypoxia marker 18F-HX4, the effective
dose estimated from monkey whole-body imaging is
higher (42 mSv/MBq) in comparison with the result ob-
tained from humans (27 mSv/MBq) However, as rodents
show excretion patterns significantly different from those
Fig. 2 [18F]-tetrafluoroborate biodistribution in macaque. Maximum-intensity projection PET images of the [18F]-tetrafluoroborate radioactivity at
different time points after intravenous injection. Time information corresponds to the mean frame time
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of primates, the non-human primate data more accurately
estimate the human dosimetry and provide a better ap-
proximation. However, it should be noted that despite the
biodistribution and metabolism of [18F]-tetrafluoroborate
which are not expected to be affected by general anaesthe-
sia, it has been reported that different anaesthetic proto-
cols have a significant effect on thyroid and salivary gland
99mTcO4
− uptake in euthyroid cats [24].
In this study, [18F]-tetrafluoroborate biodistribution in
the cynomolgus macaque closely mirrors the physiologic
distribution of NIS. In addition to the thyroid, this radio-
tracer largely distinguishes other extrathyroidal tissues
such as the gastric mucosa, salivary glands (mainly pa-
rotids), or olfactory mucosa, where NIS expression has
been demonstrated [2, 25]. In more details, [18F]-tetrafluo-
roborate was able to discriminate clearly the thyroid gland
Fig. 3 TACs for [18F]-tetrafluoroborate in organs. TACs for [18F]-tetrafluoroborate in the most prominent organs: lung, heart, kidney, stomach and
urinary bladder (a) and thyroid, olfactory mucosa, esophagus, brain and salivary glands (parotid, sublingual, submandibular) (b). Plots a and b
have different ranges of radioactivity concentrations. Curves correspond to a single animal. TACs from the other monkey showed a similar pattern
Fig. 4 TACs for [18F]-tetrafluoroborate in blood. TACs for [18F]-
tetrafluoroborate expressed as percentage of the injected dose
(ID) per gram of blood. Curves correspond to a single animal
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with an excellent signal-to-noise ratio even in the first mi-
nutes of the study (Fig. 2), as has been demonstrated pre-
viously in mice [9]. In the gastric wall, radiotracer uptake
was non-uniform, with different areas showing distinct
uptake. This fact could be explained because NIS expres-
sion in stomach wall is associated—in humans—to mucin-
secreting epithelial gastric cells [1, 3], and the distribution
of this cell type is restricted to specific areas of the ma-
caque stomach, predominantly in the gastric antrum [26].
Interestingly, epithelial gastric cells that express NIS in
human stomach are also more abundant in the antrum
[3]; so probably, final [18F]-tetrafluoroborate biodistribu-
tion in this organ could be similar between macaques and
humans. Finally, although [18F]-tetrafluoroborate is not
able to cross the blood–brain barrier, a slight uptake was
observed in the choroid plexus, where NIS expression has
also been demonstrated [2]. Interestingly, non-uptake was
showed in the testes, despite the fact that NIS transcript
and protein are expressed in germinal and Leydig cells of
human normal testes [27]. Moreover, [18F]-tetrafluorobo-
rate was seen in the organs that are responsible for excre-
tion (kidneys and bladder) or reflect the vascular phase
(heart and lungs) with an uptake in the early stage of the
study and a rapid clearance. The PET images show no
uptake in bones or joints; hence, there is no in vivo release
of [18F]-fluoride during the time frame studied, as it has
been shown in mice studies [9].
Thyroid pathologies (cancer and hyperthyroidism) are
commonly diagnosed using iodine in the form of 131I,
123I, or 124I as well with 99mTc-pertechnetate. These iod-
ine substances/radionuclides produce an effective dose
(considering a 35 % thyroid uptake), of 24, 0.22 and
15 mSv/MBq, respectively [28], all of which are higher
than the dose produced by [18F]-tetrafluoroborate
estimated in this study (0.025 mSv/MBq), which in
turn is higher than that from 99mTc-pertechnetate
(0.013 mSv/MBq).
Apart from the thyroid, the stomach is the critical
organ for [18F]-tetrafluoroborate with an absorbed dose
of 0.079 mGy/MBq, followed by the urinary bladder wall.
The organs that receive the highest absorbed dose in the
131I, 123I, or 124I studies are also the stomach (0.46, 0.068
and 0.59 mGy/MBq, respectively) and the bladder wall
(0.042, 0.06 and 0.52 mGy/MBq, respectively) [29]. On
the other hand, doses from 99mTc-pertechnetate to the
stomach and bladder are 0.026 and 0.018 mGy/MBq.
The relatively high exposure from [18F]-tetrafluoroborate
Table 2 Residence times of [18F]-tetrafluoroborate for the
measured organs and remainder of the body








Urinary bladder contents 7.66E−02 3.3E−02
Spleen 4.18E−03 7.0E−06
Red marrow 8.65E−02 1.4E−04
Remainder 2.14E+00 1.0E−01
Parotid gland 4.68E−03 2.5E−03
Submandibular gland 1.75E−03 1.1E−03
Table 3 Radiation-absorbed dose estimates for [18F]-
tetrafluoroborate based on whole-body imaging in non-human
primates





Gallbladder wall 1.46E−02 7.1E−05
LLI wall 1.42E−02 1.4E−04
Small intestine 1.43E−02 0.0E+00
Stomach wall 7.86E−02 1.9E−02
ULI wall 1.42E−02 0.0E+00







Red marrow 1.66E−02 1.4E−04






Urinary bladder wall 4.79E−02 1.5E−02
Uterus 1.56E−02 5.7E−04
Parotid glanda 4.13E−02 2.1E−02
Submandibular glanda 2.74E−02 1.7E−02
Total body 1.18E−02 1.4E−04
Effective dose equivalent (mSv/MBq) 2.21E−02 1.8E−03
Effective dose (mSv/MBq) 2.47E−02 2.8E−03
aAbsorbed dose calculated using the sphere model
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to the stomach is likely due to the to NIS expression in
the stomach wall.
Absorbed dose to the salivary glands is of interest in
patients treated with differentiated thyroid cancer, since
salivary dysfunction is the most common side effect asso-
ciated to therapies with high radioiodine activity. Thus,
submandibular and parotid average organ absorbed doses
per administered 131I activity in differentiated thyroid can-
cer treatment were estimated in 0.32 and 0.31 mGy/MBq,
respectively [21]. These values are one order of magnitude
higher than the values reported here for [18F]-tetrafluoro-
borate. In contrast, the absorbed dose to the salivary
glands from 99mTc-pertechnetate is 0.0093 mGy/MBq.
In conclusion, [18F]-tetrafluoroborate provides quanti-
tative PET images of high quality with an absorbed dose
slightly higher than the dose produced by 99mTc-per-
technetate and much lower than the doses from iodine
compounds. This fact supports its use for PET imaging
of NIS for diagnosis of disease and monitoring treatment
for thyroid cancer and hyperthyroidism. However, hu-
man studies with [18F]-tetrafluoroborate will validate the
biodistribution and dosimetry performed in this study
with cynomolgus monkeys.
Conclusions
We have determined the biodistribution and calculated
the absorbed doses after intravenous administration of
[18F]-tetrafluoroborate in cynomolgus monkeys, by whole-
body PET imaging and OLINDA calculations methods.
The biodistribution closely mirrors physiologic distribu-
tion of NIS. The effective dose is 0.025 mSv/MBq, and the
critical organs are the stomach wall, the urinary bladder
wall, and the thyroid.
Additional file
Additional file 1: 3D video of dynamic [18F]-tetrafluoroborate
biodistribution. (MOV 776 kb)
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